CTOs on the Move

STEMCELL Technologies

www.stemcell.com

 
STEMCELL Technologies is a biotechnology company that develops specialty cell culture media and cell separation products to support research in the fields of immunology, hematology, neuroscience, mesenchymal cell, stem cell and epithelial cell biology. We also provide instruments, cytokines, antibodies, training courses, proficiency testing and contract assay services. Driven by science and a passion for quality, STEMCELL delivers over 2500 products to more than 80 countries worldwide. STEMCELL Technologies provides consistent, unfailing quality and one-on-one assistance to help you succeed. We do this because we love science as much as you do.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.stemcell.com
  • 1618 Station Street
    Vancouver, BC CAN V6A 1B6
  • Phone: 604.877.0713

Executives

Name Title Contact Details

Similar Companies

Seer

Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.

Beigene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan.

Lyell

We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.

Access BIO

Access BIO is a Boyce, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Professional Imaging Consultants

Professional Imaging Consultants is a Winter Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.